Teleflex Incorporated Q2 FY2026 earnings call

New CEO Transition

• New CEO Jason Weidman (note: typo correction from transcript mislabeling, Lawrence Kirsch is IR head) has spent two months assessing the global business, meeting employees, customers and physicians, and reviewing portfolio and growth opportunities. He confirmed confidence in the existing strategic transformation plan, noting a strong foundation of market-leading products, strong brands, and a global commercial footprint, with significant untapped growth opportunity.

Strategic Transformation & Divestitures

• The OEM strategic divestiture has closed successfully, generating ~$1.5 billion in gross proceeds and ~$1.25 billion in after-tax proceeds. The majority of these proceeds are being used for $700 million in debt paydown and accelerated share repurchases.
• The acute care and interventional urology divestitures are still pending regulatory review; the FTC issued a second request for additional information in March 2026, and both parties are cooperating. Closing is currently anticipated for Q4 2026, subject to regulatory approval.
• The divestiture program will create a more focused portfolio centered on core critical care and high acuity hospital markets, strengthen financial flexibility, and reduce stranded costs over time.

Innovation Milestones

• R&D investment has increased to 7.9% of sales in H1 2026, up from historical levels around 6%.
• In late July 2026, the FDA granted BLA approval for EasyPlaz freeze-dried plasma, the first FDA-licensed freeze-dried plasma product. EasyPlaz addresses an unmet need for plasma transfusion in pre-hospital, combat, and emergency settings where traditional plasma products are logistically impractical. Initial commercial priority is the U.S. military and government market, with commercial launch expected to contribute meaningfully to revenue in 2027.
• The Freesolve (previously referenced as Freeze-all) novel drug-eluting resorbable magnesium scaffold program hit key clinical milestones: 4-year sustained positive safety and performance data from the single-arm Biomag-1 study was presented in May 2026; patient enrollment for the first international randomized trial (Biomag-2) completed ahead of schedule, with data readout expected in late 2027; the U.S. pivotal randomized trial (BioMag-3) initiated enrollment with the first patient procedures completed in June 2026.

Capital Allocation

• The company remains committed to the previously announced plan of $1 billion in total share repurchases and $800 million in total debt reduction following divestiture closings. $250 million in open market share repurchases were completed in Q2 2026, and an additional $250 million accelerated share repurchase will commence August 7, 2026.
• At quarter-end, net leverage was ~2.8x; pro forma for the OEM divestiture, net leverage was ~1.9x.

VI Integration Update

• Integration of the acquired Biotronic Vascular Intervention business is taking longer than originally anticipated, with the timeline for full completion extended from mid-2026 to the second half of 2026. All integration challenges are considered temporary and include order-to-cash transitions, distributor inventory transitions, and Salesforce alignment and hiring.

For Q2 2026 continuing operations, Teleflex reported total revenues of $570.3 million, up 28.9% year-over-year on a GAAP basis and 4.7% on a pro forma adjusted constant currency basis. The performance breakdown by product segment is as follows: 1. Vascular: Revenue was $246.3 million, an 8% year-over-year increase, contributing 43.2% of total Q2 revenue. Growth was driven by hemostatic products and the central access portfolio. 2. Surgical: Revenue was $112.1 million, a 9.2% year-over-year increase, contributing 19.7% of total Q2 revenue. Growth was led by strong performance in ligation clips, the instrument portfolio, and skin stapling. 3. Interventional: Revenue was $211.9 million, a 1% year-over-year decrease, contributing 37.1% of total Q2 revenue. While multiple product categories outperformed expectations, overall results were soft due to ongoing integration and restructuring activities from the BI (Biotronic Vascular Intervention) acquisition.

• Full-year 2026 pro forma adjusted constant currency revenue growth guidance was revised downward to 3.5% to 4.5%, from the prior range of 4.5% to 5.5%. The downward revision reflects the slower-than-expected interventional business integration and moderated second half growth expectations for the vascular and surgical segments, with the low end of the range assuming no improvement in interventional revenues from Q2 levels through year-end plus typical Q3 seasonality.
• Full-year 2026 adjusted operating margin guidance is maintained at ~19%, with a long-term steady state target of ~23% after stranded costs from divestitures are fully addressed.
• Full-year 2026 adjusted EPS guidance was increased to $6.90 to $7.20, up from the prior range of $6.25 to $6.50. The increase reflects the benefit of completed share repurchases and lower expected net interest expense following debt reduction from the OEM divestiture. This guidance excludes any potential benefit from additional share repurchases from the pending acute care/interventional urology divestiture proceeds or any IEFA tariff refunds.
• Full-year 2026 net interest expense guidance was lowered to ~$85 million, down from the prior expectation of ~$105 million, reflecting $700 million in debt paydown from OEM divestiture proceeds.
• Full-year 2026 adjusted tax rate guidance was lowered to ~12.25%, from the prior expectation of ~13.5%.
• The multi-year restructuring plan launched in 2026, targeting $50 million in annual pre-tax cost savings by mid-2028, remains on track, with savings expected to accelerate in the second half of 2026.
• Management expects meaningful step-ups in adjusted operating margin, adjusted operating income, and adjusted EPS EPS starting in 2027 after integration and divestiture transitions are complete, driven by share repurchases, balance sheet deleveraging, cost savings, and margin expansion.

• The integration of the acquired Biotronic Vascular Intervention business has taken longer than expected, with lingering temporary disruptions impacting near-term interventional segment revenue. While management expects all issues to be resolved by end-2026, delays in resolving integration challenges could further pressure near-term results.
• The pending acute care and interventional urology divestitures are subject to FTC regulatory review, and closing timing is uncertain, which impacts the pace of additional capital deployment for share repurchases and debt reduction.
• Stranded costs associated with completed and pending divestitures will continue to pressure near-term margins through 2026, with full margin expansion not expected until 2027 after transition service agreements expire and costs are fully restructured.
• The clinical success of the Freesolve scaffold program is not guaranteed; even positive trial data may require additional work to update clinical guidelines outside the U.S. to support broad adoption.
• Potential tariff refunds from the U.S. government have uncertain timing, and any benefit will only be recognized upon official confirmation, creating uncertainty around potential incremental upside to 2026 results.
• New CMS reimbursement rules eliminate the breakthrough designation shortcut for enhanced reimbursement, requiring additional clinical superiority data for products like Freesolve, which could impact future pricing and adoption.

Q: The analyst asked what specific issues are delaying the BI (Vascular Intervention) integration, when these issues will be resolved, and which parts of the business are most impacted. / A: Management clarified that there are no product-related issues, as the legacy Teleflex and BI product portfolios are highly complementary and well-received by key opinion leaders. The three main categories of transient integration issues are order-to-cash transitions (which caused customer confusion that the company is systematically resolving), distributor inventory transitions (where legacy distributors are drawing down inventory before new distributors start purchasing), and sales force transitions (including territory realignment, new product training, and open headcount that the company is actively hiring to fill). Management confirmed that the BI revenue base was disproportionately impacted by these disruptions, and that the company has strong confidence all issues will be resolved by the end of 2026, in line with the updated guidance timeline.

Q: The analyst asked what the market opportunity is for newly FDA-approved EasyPlaz, when the commercial launch will occur, and when revenue will begin to ramp. / A: Management stated that the immediate top priority is serving the U.S. military and government market. Next steps include completing a Department of Defense procurement solicitation, negotiating a contract, and then starting commercial delivery. Any revenue from EasyPlaz in 2026 is expected to be immaterial, with meaningful contribution starting in 2027. Management noted that while an old estimate pegged the long-term U.S. market opportunity at $100 million, the new leadership team is currently reassessing the total opportunity and will share updated details once the review is complete.

Q: The analyst asked what the expected timeline is for the new CEO to share the outcome of his full strategic review and a formal long-range plan for the company. / A: Management explained that the CEO has only been in the role for two months, and is still conducting a comprehensive assessment of the entire business. The company expects to share additional color on the long-term strategic direction and formal plan by the next earnings call. The CEO confirmed he remains confident in the existing transformative divestiture strategy and sees no current reason to shift course, but is developing additional long-term plans to drive sustainable growth.

Q: The analyst asked for an update on the capital allocation plan, specifically the balance between future share repurchases, debt paydown, and potential M&A activity. / A: Management reaffirmed commitment to the existing plan of $1 billion in total share repurchases and $800 million in total debt reduction. To date, $500 million in share repurchases have been completed or announced, with the remaining $500 million expected to come from proceeds of the pending acute care and interventional urology divestiture. $700 million of the $800 million committed debt reduction has already been completed. For M&A, management stated the current focus is executing on existing divestitures and integration, and the company will not pursue any large transformational acquisitions in the short-to-medium term.